ASND
NASDAQAscendis Pharma A/S
News · 26 weeks82-8%
2025-12-282026-06-21
Mix3890d
- SEC Filings14(37%)
- Other14(37%)
- Insider7(18%)
- Earnings2(5%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRPhase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with HypoparathyroidismMulti-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year trial COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems –
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PR5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatment COPENHAGEN, Denmark, June 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced 5-year (Week 266) data from its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the five-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – kidney
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRAscendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026. "As a leader in rare endocrine diseases, we are committed to sharing comprehensive clinical trial results in peer-reviewed forums that reinforce the transformative potential of our innovative therapies," said Aimee Shu, M.D., Executive Vice President, Chief Medical Officer at Ascendis
- INSIDEREVP & Chief Financial Officer Smith Scott Thomas bought $21,900 worth of Ordinary Shares (100 units at $219.00), increasing direct ownership by 2% to 4,367 units (SEC Form 4)4 - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDERDirector Bienaime Jean Jacques bought $111,562 worth of Ordinary Shares (500 units at $223.12), increasing direct ownership by 125% to 900 units (SEC Form 4)4 - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDEREVP & Chief Financial Officer Smith Scott Thomas bought $55,830 worth of Ordinary Shares (250 units at $223.32), increasing direct ownership by 6% to 4,267 units (SEC Form 4)4 - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDERAmendment: New insider Smith Scott Thomas claimed ownership of 4,017 units of Ordinary Shares (SEC Form 3)3/A - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDERDirector Bienaime Jean Jacques bought $95,120 worth of Ordinary Shares (400 units at $237.80) (SEC Form 4)4 - Ascendis Pharma A/S (0001612042) (Issuer)
- SECSEC Form SD filed by Ascendis Pharma A/SSD - Ascendis Pharma A/S (0001612042) (Filer)
- ANALYSTCitigroup initiated coverage on Ascendis Pharma with a new price targetCitigroup initiated coverage of Ascendis Pharma with a rating of Buy and set a new price target of $355.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/SSCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/SSCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- INSIDEROfficer Jensen Flemming Steen sold $4,641,021 worth of Ordinary Shares (19,460 units at $238.49), closing all direct ownership in the company (SEC Form 4)4 - Ascendis Pharma A/S (0001612042) (Issuer)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRAscendis Pharma Reports First Quarter 2026 Financial Results- Q1 2026 revenue of €197 million for YORVIPATH® and €44 million for SKYTROFA® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL® enrollments since early April U.S. commercial launch - Entered into agreement to sell Rare Pediatric Disease Priority Review Voucher for $187.5 million - Conference call today at 8:00 am ET COPENHAGEN, Denmark, May 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the first quarter ended March 31, 2026, and provided a business update. "The FDA approval of YUVIWEL, our third consecutive TransCon product, and the robust patient uptake for YORVIPATH
- PRNew 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 YearsCOPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new data from a subgroup analysis showing that children with achondroplasia ≥5 years of age at enrollment treated with once-weekly TransCon CNP (navepegritide) in its pivotal ApproaCH Trial demonstrated significantly greater annualized growth velocity (AGV) compared to placebo at Week 52, and sustained these growth improvements through up to two years of treatment. The safety profile for this subgroup through up to two years of treatment was similar to the overall population, with a low rate of injection site reactions (ISRs, all mild), no symptomatic hypotension, and no acceleration of
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/SSCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
- PRAscendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thursday, May 7, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on May 7, 2026, at 8:00 a.m. Eastern Time (ET) to discuss its first quarter 2026 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.asce
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
ASND FAQ
7 questionsWhat does Ascendis Pharma A/S do?
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup...Where does ASND stock trade?
Ascendis Pharma A/S (ASND) is listed on NASDAQ.What sector and industry is ASND in?
Ascendis Pharma A/S operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ascendis Pharma A/S go public?
Ascendis Pharma A/S (ASND) completed its IPO in 2015.What are analysts saying about ASND?
Ascendis Pharma A/S has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy on 2026-05-19.What companies are similar to ASND?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ASND side-by-side with any of them on Quantisnow.How can I track ASND on Quantisnow?
Quantisnow aggregates Ascendis Pharma A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ASND to receive live email and push alerts on every new disclosure.